Limits...
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.

Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T - Cancer Sci. (2014)

Bottom Line: Secondary objectives included safety and tolerability, pharmacokinetics, antitumor activity and pharmacodynamic marker changes.Pharmacokinetic results showed that buparlisib was rapidly absorbed in a dose-proportional manner.Best overall response was stable disease for six patients, including one unconfirmed partial response.

View Article: PubMed Central - PubMed

Affiliation: Nagoya University Hospital, Nagoya, Japan.

Show MeSH

Related in: MedlinePlus

Duration of buparlisib treatment according to dose and radiologic response. Study participants are shown according to primary tumor site, buparlisib dose, days on trial and tumor response according to Response Evaluation Criteria In Solid Tumors v1.0. PD, progressive disease; SD, stable disease; UNK, unknown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317947&req=5

fig02: Duration of buparlisib treatment according to dose and radiologic response. Study participants are shown according to primary tumor site, buparlisib dose, days on trial and tumor response according to Response Evaluation Criteria In Solid Tumors v1.0. PD, progressive disease; SD, stable disease; UNK, unknown.

Mentions: The best overall response was stable disease for six patients and progressive disease for seven patients (Table3; Fig.2). The best percentage change from baseline in target lesions for all patients is also shown in Fig. S1. The duration of stable disease ranged from 55 to 116 days. The disease control rate, defined as rates of complete response plus partial response plus stable disease, was 40%.


Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.

Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T - Cancer Sci. (2014)

Duration of buparlisib treatment according to dose and radiologic response. Study participants are shown according to primary tumor site, buparlisib dose, days on trial and tumor response according to Response Evaluation Criteria In Solid Tumors v1.0. PD, progressive disease; SD, stable disease; UNK, unknown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317947&req=5

fig02: Duration of buparlisib treatment according to dose and radiologic response. Study participants are shown according to primary tumor site, buparlisib dose, days on trial and tumor response according to Response Evaluation Criteria In Solid Tumors v1.0. PD, progressive disease; SD, stable disease; UNK, unknown.
Mentions: The best overall response was stable disease for six patients and progressive disease for seven patients (Table3; Fig.2). The best percentage change from baseline in target lesions for all patients is also shown in Fig. S1. The duration of stable disease ranged from 55 to 116 days. The disease control rate, defined as rates of complete response plus partial response plus stable disease, was 40%.

Bottom Line: Secondary objectives included safety and tolerability, pharmacokinetics, antitumor activity and pharmacodynamic marker changes.Pharmacokinetic results showed that buparlisib was rapidly absorbed in a dose-proportional manner.Best overall response was stable disease for six patients, including one unconfirmed partial response.

View Article: PubMed Central - PubMed

Affiliation: Nagoya University Hospital, Nagoya, Japan.

Show MeSH
Related in: MedlinePlus